Medical device companies Arrotek and NeedleTech are merging under the Arrotek brand. The combined company will aim to offer extended and enhanced medical device design and manufacturing services to medtech organisations across the globe, particularly in the US and EU.
![Press Release Image 1[78] copy.jpg](https://www.med-technews.com/downloads/9253/download/Press%20Release%20Image%201%5B78%5D%20copy.jpg?cb=8a4afc1e49a7e0afe7c0daeee501c76b&w={width}&h={height} "Press Release Image 1[78] copy.jpg")
Damien McGinley
Both Arrotek and NeedleTech have strong records in the medical device industry, serving a broad range of customers that include OEMs, medical device start-ups, and corporations. The medical device products and components they design, develop, and manufacture are used by healthcare professionals around the world.
The new combined company will build on the current foundations of quality, flexibility, and industry-leading innovation while merging the skills, capabilities, and knowledge across both business units.
Industry award-winning company Arrotek is a specialist in the design, development, and manufacture of interventional and diagnostic catheters. NeedleTech is an industry leader in the design and manufacture of specialty medical needles, cannulas, and stylets.
The Arrotek and NeedleTech brands are part of the Theragenics group of companies.
Mark Pugh, director of the OEM Group, said: “I am delighted to announce the merger of our two current brands, Arrotek and NeedleTech. This merger will enhance our current offering, extending the services we provide. We are also investing in our shared engineering departments to put the structures in place to take our business forward.
“I would like to take this opportunity to thank our current customers for their continued support. As a combined team, we are looking forward to enhancing the services we offer and strengthening our partnerships together.”
The new venture will comprise two centres of excellence, with the operation in Massachusetts focusing on metal components and the Irish facility concentrating on plastics.
Pugh added: “It’s an exciting time for this new venture, especially given the strengths of our teams across both facilities in the US and EU.
“This is also an exciting time for the medical device industry and wider healthcare sector as advances in technologies and therapeutics open the door to new and cutting-edge treatments. Patient outcomes are being transformed by these new and innovative treatments, and this is only going to accelerate.
“Every member of our team, whether located in our US facility in Massachusetts or our EU facility in Ireland, is dedicated to remaining at the forefront of minimally invasive medical device development where we can continue driving innovation in healthcare.”
